Migraine With Aura Clinical Trial
Official title:
Investigations of the Endogenous Vasoconstrictor and Neuromodulator Peptide Endothelin-1 as a Potential Trigger of Migraine Aura
One third of migraine patients experience aura, i.e. dramatic, transient neurological
symptoms, most often in the form of visual disturbances, that usually appear before the onset
of migraine headache. The likely underlying mechanism of aura is known as cortical spreading
depression, a wave of changes in electrical activity that slowly spreads in the outermost
layer of the brain. It is currently not known what causes the aura to initiate in patients or
what the relationship is between aura and migraine headache, e.g. if treatment targeted at
aura mechanisms will prevent subsequent headache. Due to the short-lasting and unpredictable
nature of aura, the only possible approach for systematic investigations is to experimentally
trigger aura, but currently no method for aura-triggering is available.
The overall goal of the proposed project is to reveal the earliest mechanisms of the migraine
attack by investigating the initiating factors of aura in the migraine brain.
Current animal evidence indicates that infusion of endothelin-1 (ET-1), a naturally occurring
signaling molecule released from blood vessels, is safe and very likely to trigger migraine
aura in patients.
In this project the investigators aim to study the effects of ET-1 on the human brain, to
investigate aura-inducing effects of ET-1 in patients and to develop a safe and reliable
method for the experimental induction of migraine aura using ET-1.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02253004 -
Induction of Migraine Aura With Cilostazol
|
Phase 0 | |
| Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
| Completed |
NCT00123201 -
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
|
Phase 2 | |
| Completed |
NCT04406649 -
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
|
Phase 3 | |
| Completed |
NCT03874832 -
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05565001 -
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.
|
N/A | |
| Recruiting |
NCT05416476 -
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
|
Phase 3 | |
| Recruiting |
NCT00893594 -
Efficacy of Sumatriptan With Naprosyn in Migraine With Aura
|
N/A | |
| Completed |
NCT01388699 -
Migraine and Endothelial Dysfunction
|
||
| Completed |
NCT00534560 -
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
|
Phase 2 | |
| Terminated |
NCT04936061 -
Transnasal Cooling for Migraine
|
N/A | |
| Recruiting |
NCT05281770 -
Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
|
||
| Not yet recruiting |
NCT04063540 -
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
|
Phase 2 | |
| Completed |
NCT03472417 -
Partial Rebreathing in the Treatment of Migraine With Aura
|
N/A | |
| Completed |
NCT00334178 -
Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine
|
Phase 3 | |
| Recruiting |
NCT06051604 -
Mi-Helper Transnasal Cooling for Acute Treatment of Migraine
|
N/A | |
| Completed |
NCT03472378 -
Can DFN-15 Terminate Migraine With Allodynia?
|
Phase 2 | |
| Recruiting |
NCT05211154 -
Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine
|
Phase 4 | |
| Completed |
NCT02708797 -
Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura.
|
N/A | |
| Recruiting |
NCT00877838 -
Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura
|
Phase 2 |